Market potentials of ALK vaccination as a new strategy for the cure of ALK positive tumors such as lymphoma, lung carcinoma and neuroblastoma

Project Information

ALKVAX

Grant agreement ID: 324621

Project closed

Start date 1 June 2013

End date 31 May 2014

Funded under

• Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Total cost € 166 933,60

EU contribution € 149 938,96

Coordinated by

UNIVERSITA DEGLI STUDI DI TORINO
Italy